drugset / Trial / NCT03109600

Safety and Immunogenicity of Vi-DT Typhoid Conjugate Vaccine (Bio Farma) in Adults and Children (Phase I)

NCT03109600

Phase 1 Completed 100 enrolled PT Bio Farma
RandomizedParallel-groupSingle-blindPrevention

Summary

This study is to assess the safety of Vi-DT vaccine in adults and children.

Timeline

Start
2017-04-18
Primary completion
2017-09-28
Completion
2018-02-19

Drugs

EvaluationDrugModalityDoseRoute
Comparator Influenza Virus Vaccine Vaccine
Comparator Prevnar 13 Vaccine
Comparator Vi Polysaccharide Vaccine Vaccine 0.5 ml
Subject Vi-DT Vaccine 0.5 ml

Indications

No indication recorded.